Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Canada

Juravinski Cancer Centre, Hamilton, Ontario

The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario

Jewish General Hospital, Montreal, Quebec